
|Articles|September 16, 2008
It's all changing at Zeiss
Recent acquisitions, division restructuring, and management changes prove that Carl Zeiss Meditec is very much committed to change. Ophthalmology Times Europe spoke with CEO, Dr Michael Kaschke about the challenges that he faces in an ever evolving market.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
4
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
5













































